MARKET

ENGN

ENGN

enGene Holdings Inc.
NASDAQ
8.22
+0.22
+2.75%
Closed 18:14 12/04 EST
OPEN
8.00
PREV CLOSE
8.00
HIGH
8.24
LOW
7.96
VOLUME
190.83K
TURNOVER
0
52 WEEK HIGH
11.14
52 WEEK LOW
2.650
MARKET CAP
530.83M
P/E (TTM)
-4.3250
1D
5D
1M
3M
1Y
5Y
1D
Wells Fargo Sticks to Its Buy Rating for enGene Holdings (ENGN)
TipRanks · 1d ago
Strong Buy Rating for enGene Driven by Regulatory Advancements and Market Readiness of Detalimogene
TipRanks · 2d ago
enGene’s Detalimogene Chosen for FDA Manufacturing Pilot Program
TipRanks · 2d ago
enGene Reports 62% Complete Response Rate for Detalimogene in Bladder Cancer Trial
Reuters · 2d ago
enGene detalimogene voraplasmid selected for FDA manufacturing pilot program
TipRanks · 2d ago
enGene Holdings Says FDA Selects Detalimogene Voraplasmid To Participate In Chemistry, Manufacturing, And Controls Development And Readiness Pilot Program
Benzinga · 2d ago
ENGENE’S DETALIMOGENE SELECTED FOR FDA MANUFACTURING PILOT PROGRAM TO SUPPORT MANUFACTURING READINESS
Reuters · 3d ago
ENGENE HOLDINGS - FDA SELECTS DETALIMOGENE VORAPLASMID TO PARTICIPATE IN CHEMISTRY, MANUFACTURING, & CONTROLS DEVELOPMENT & READINESS PILOT PPROGRAM
Reuters · 3d ago
More
About ENGN
enGene Holdings Inc. is a clinical-stage biotechnology company mainstreaming genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. The Company’s lead program is detalimogene voraplasmid, (detalimogene) for patients with non-muscle invasive bladder cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase II study, which includes a cohort studying detalimogene in Bacillus Calmette-Guerin (BCG)-unresponsive patients with carcinoma in situ (Cis). Detalimogene is being developed through its proprietary Dually Derivatized Oligochitosan (DDX) platform, which enables penetration of mucosal tissues and delivery of a wide range of sizes and types of cargo, including DNA and various forms of RNA. The Company is developing non-viral genetic medicines based on its DDX gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.

Webull offers enGene Holdings Inc stock information, including NASDAQ: ENGN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ENGN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ENGN stock methods without spending real money on the virtual paper trading platform.